TABLE 2.
Sulfation of Triclosan and Tolvaptan by Individual Human SULTs
| SULT | pmol.min−1.mg cell lysate protein−1 |
|
|---|---|---|
| Triclosana | Tolvaptanb | |
|
| ||
| 1A1 | 15.2 ± 1.5 | n.d. |
| 1A2 | 193 ± 4.3 | n.d. |
| 1A3 | 182 ± 9.6 | n.d. |
| 1B1 | 199 ± 9.8 | 9.0 ± 0.3 |
| 1C2 | 38.6 ± 3.4 | n.d. |
| 1C3 | 22.9 ± 2.8 | 18.5 ± 0.5 |
| 1C4 | 210 ± 12.8 | n.d. |
| 1E1 | 190 ± 4.0 | 2.3 ± 0.1 |
| 2A1 | 26.7 ± 4.7 | 13.8 ± 0.6 |
| 2B1 | 34.1 ± 1.0 | 2.3 ± 0.2 |
| 4A1 | 20.8 ± 1.6 | n.d. |
| 6B1 | 8.9 ± 0.3 | n.d. |
Sulfation assays were conducted in a 125 μl final reaction volume by incubating 0.25 mM [2,4-dichlorophenyl-14C(U)]triclosan (specific activity: 22.9 mCi/mmol) with 1.2 mg cell lysate proteins, 2 mM EDTA, 0.5 mM PAPS, and 100 mM sodium phosphate, pH 7.2, at 37°C for 2 h. Reactions were terminated by the addition of an equal volume of ice-cold methanol. Precipitated material was removed by centrifugation at 14,000 g at 4°C for 30 min and the supernatants were analyzed for tolvaptan and tolvaptan sulfate by a reversed-phase HPLC with radiochemical detection as previously described (Fang et al., 2014).
Sulfation assays using 0.2 mM tolvaptan at 37°C for 1 h, as described in Materials and Methods. n.d.: not detected.